{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:28:51Z","timestamp":1791462531347,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0904"],"award-info":[{"award-number":["W81XWH-20-1-0904"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110909"],"award-info":[{"award-number":["W81XWH2110909"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["Hypatia"],"award-info":[{"award-number":["Hypatia"]}],"id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114570"],"award-info":[{"award-number":["70114570"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL131835"],"award-info":[{"award-number":["R01HL131835"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009784","name":"Starr Foundation","doi-asserted-by":"publisher","award":["I15-0026"],"award-info":[{"award-number":["I15-0026"]}],"id":[{"id":"10.13039\/100009784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41375-026-02892-8","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:57:20Z","timestamp":1772099840000},"page":"783-793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-153X","authenticated-orcid":false,"given":"Jonas S.","family":"Jutzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edie","family":"Crosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulwoo J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"van Gasteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Laurore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7393-861X","authenticated-orcid":false,"given":"Benjamin","family":"Rolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Tishena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena V.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Wazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-6212","authenticated-orcid":false,"given":"Lachelle D.","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0117","authenticated-orcid":false,"given":"Joan","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-0344","authenticated-orcid":false,"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Graubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-1063","authenticated-orcid":false,"given":"Robert K.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-0581","authenticated-orcid":false,"given":"Anna E.","family":"Marneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2892_CR1","doi-asserted-by":"crossref","unstructured":"Visconte V, MON, HJR. Mutations in splicing factor genes in myeloid malignancies: significance and impact on clinical features. Cancers. 2019;11:1844.","DOI":"10.3390\/cancers11121844"},{"key":"2892_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u20139.","journal-title":"Nature"},{"key":"2892_CR3","first-page":"160","volume":"1","author":"EN Oliva","year":"2011","unstructured":"Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res. 2011;1:160\u20136.","journal-title":"Am J Blood Res"},{"key":"2892_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22\u201333.","journal-title":"N Engl J Med"},{"key":"2892_CR5","first-page":"41","volume":"26","author":"A Vaya","year":"2002","unstructured":"Vaya A, Mira Y, Martinez M, Villa P, Ferrando F, Estelles A, et al. Biological risk factors for deep vein thrombosis. Clin Hemorheol Microcirc. 2002;26:41\u201353.","journal-title":"Clin Hemorheol Microcirc"},{"key":"2892_CR6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2012.08.011","volume":"36","author":"A Tefferi","year":"2012","unstructured":"Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk Res. 2012;36:1481\u20139.","journal-title":"Leuk Res"},{"key":"2892_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.22","volume":"6","author":"D Barraco","year":"2016","unstructured":"Barraco D, Elala YC, Lasho TL, Begna KH, Gangat N, Finke C, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6:e415.","journal-title":"Blood Cancer J"},{"key":"2892_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3324\/haematol.2018.195552","volume":"104","author":"H Wouters","year":"2019","unstructured":"Wouters H, van der Klauw MM, de Witte T, Stauder R, Swinkels DW, Wolffenbuttel BHR, et al. Association of anemia with health-related quality of life and survival: a large population-based cohort study. Haematologica. 2019;104:468\u201376.","journal-title":"Haematologica"},{"key":"2892_CR9","doi-asserted-by":"crossref","unstructured":"Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med. 2020;10:a034876.","DOI":"10.1101\/cshperspect.a034876"},{"key":"2892_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.exphem.2020.07.011","volume":"89","author":"RF Paulson","year":"2020","unstructured":"Paulson RF, Hariharan S, Little JA. Stress erythropoiesis: definitions and models for its study. Exp Hematol. 2020;89:43\u201354.e2.","journal-title":"Exp Hematol"},{"key":"2892_CR11","doi-asserted-by":"crossref","unstructured":"Tichil I, Mitre I, Zdrenghea MT, Bojan AS, Tomuleasa CI, Cenariu D. A Review of Key Regulators of Steady-State and Ineffective Erythropoiesis. J Clin Med. 2024;13:2585.","DOI":"10.3390\/jcm13092585"},{"key":"2892_CR12","doi-asserted-by":"publisher","first-page":"e01913","DOI":"10.7554\/eLife.01913","volume":"3","author":"ZA Knight","year":"2014","unstructured":"Knight ZA, Schmidt SF, Birsoy K, Tan K, Friedman JM. A critical role for mTORC1 in erythropoiesis and anemia. Elife. 2014;3:e01913.","journal-title":"Elife"},{"key":"2892_CR13","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1128\/MCB.00398-09","volume":"29","author":"C Brignatz","year":"2009","unstructured":"Brignatz C, Paronetto MP, Opi S, Cappellari M, Audebert S, Feuillet V, et al. Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Mol Cell Biol. 2009;29:6438\u201348.","journal-title":"Mol Cell Biol"},{"key":"2892_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ajh.25295","volume":"94","author":"E Beneduce","year":"2019","unstructured":"Beneduce E, Matte A, De Falco L, Mbiandjeu S, Chiabrando D, Tolosano E, et al. Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis. Am J Hematol. 2019;94:10\u201320.","journal-title":"Am J Hematol"},{"key":"2892_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617\u201330.","journal-title":"Cancer Cell"},{"key":"2892_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00552-x","volume":"11","author":"D Liu","year":"2021","unstructured":"Liu D, Xu Z, Zhang P, Qin T, Li B, Qu S, et al. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer J. 2021;11:154.","journal-title":"Blood Cancer J"},{"key":"2892_CR17","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","volume":"120","author":"SJ Wu","year":"2012","unstructured":"Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120:3106\u201311.","journal-title":"Blood"},{"key":"2892_CR18","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","volume":"4","author":"C Gardin","year":"2020","unstructured":"Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4:1942\u20139.","journal-title":"Blood Adv"},{"key":"2892_CR19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"2892_CR20","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","volume":"34","author":"SA Bamopoulos","year":"2020","unstructured":"Bamopoulos SA, Batcha AMN, Jurinovic V, Rothenberg-Thurley M, Janke H, Ksienzyk B, et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020;34:2621\u201334.","journal-title":"Leukemia"},{"key":"2892_CR21","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","volume":"103","author":"VV Prassek","year":"2018","unstructured":"Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103:1853\u201361.","journal-title":"Haematologica"},{"key":"2892_CR22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer","year":"2013","unstructured":"Cancer, Genome, Atlas, Research N, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2892_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ng.3371","volume":"47","author":"VP Lavallee","year":"2015","unstructured":"Lavallee VP, Baccelli I, Krosl J, Wilhelm B, Barabe F, Gendron P, et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet. 2015;47:1030\u20137.","journal-title":"Nat Genet"},{"key":"2892_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2892_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","volume":"132","author":"A Pellagatti","year":"2018","unstructured":"Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood. 2018;132:1225\u201340.","journal-title":"Blood"},{"key":"2892_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16179-8","volume":"11","author":"K Leonards","year":"2020","unstructured":"Leonards K, Almosailleakh M, Tauchmann S, Bagger FO, Thirant C, Juge S, et al. Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia. Nat Commun. 2020;11:2807.","journal-title":"Nat Commun"},{"key":"2892_CR27","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/humu.21077","volume":"30","author":"P Bianchi","year":"2009","unstructured":"Bianchi P, Fermo E, Vercellati C, Boschetti C, Barcellini W, Iurlo A, et al. Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the SEC23B gene. Hum Mutat. 2009;30:1292\u20138.","journal-title":"Hum Mutat"},{"key":"2892_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12860-021-00398-y","volume":"22","author":"C Tan","year":"2021","unstructured":"Tan C, Liu X, Zhang X, Peng W, Wang H, Zhou W, et al. Fyn kinase regulates dopaminergic neuronal apoptosis in animal and cell models of high glucose (HG) treatment. BMC Mol Cell Biol. 2021;22:58.","journal-title":"BMC Mol Cell Biol"},{"key":"2892_CR29","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594\u2013603.","journal-title":"J Clin Oncol"},{"key":"2892_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25673","volume":"95","author":"V Madan","year":"2020","unstructured":"Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, et al. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. Am J Hematol. 2020;95:133\u201343.","journal-title":"Am J Hematol"},{"key":"2892_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00947-y","volume":"13","author":"Y Yang","year":"2023","unstructured":"Yang Y, Abbas S, Sayem MA, Dutta A, Mohi G. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm. Blood Cancer J. 2023;13:171.","journal-title":"Blood Cancer J"},{"key":"2892_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41375-023-01878-0","volume":"37","author":"C Willekens","year":"2023","unstructured":"Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, et al. SRSF2-P95H decreases JAK\/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023;37:1287\u201397.","journal-title":"Leukemia"},{"key":"2892_CR33","doi-asserted-by":"crossref","unstructured":"Wojtuszkiewicz A, van der Werf I, Hutter S, Walter W, Baer C, Kern W, et al. Maturation state-specific alternative splicing in FLT3-ITD and NPM1 Mutated AML. Cancers. 2021;13:3929.","DOI":"10.3390\/cancers13163929"},{"key":"2892_CR34","doi-asserted-by":"publisher","first-page":"24772","DOI":"10.1074\/jbc.M115.687020","volume":"290","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yamada E, Zong H, Pessin JE. Fyn Activation of mTORC1 Stimulates the IRE1alpha-JNK Pathway, Leading to Cell Death. J Biol Chem. 2015;290:24772\u201383.","journal-title":"J Biol Chem"},{"key":"2892_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bjh.14057","volume":"174","author":"J Wang","year":"2016","unstructured":"Wang J, Tran J, Wang H, Guo C, Harro D, Campbell AD, et al. mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease. Br J Haematol. 2016;174:461\u20139.","journal-title":"Br J Haematol"},{"key":"2892_CR36","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/ajh.23786","volume":"89","author":"X Zhang","year":"2014","unstructured":"Zhang X, Camprecios G, Rimmele P, Liang R, Yalcin S, Mungamuri SK, et al. FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. Am J Hematol. 2014;89:954\u201363.","journal-title":"Am J Hematol"},{"key":"2892_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bcmd.2015.08.001","volume":"55","author":"A Khaibullina","year":"2015","unstructured":"Khaibullina A, Almeida LE, Wang L, Kamimura S, Wong EC, Nouraie M, et al. Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. Blood Cells Mol Dis. 2015;55:363\u201372.","journal-title":"Blood Cells Mol Dis"},{"key":"2892_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bjh.15665","volume":"185","author":"AA Al-Khatti","year":"2019","unstructured":"Al-Khatti AA, Alkhunaizi AM. Additive effect of sirolimus and hydroxycarbamide on fetal haemoglobin level in kidney transplant patients with sickle cell disease. Br J Haematol. 2019;185:959\u201361.","journal-title":"Br J Haematol"},{"key":"2892_CR39","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1111\/ajt.14263","volume":"17","author":"N Gaudre","year":"2017","unstructured":"Gaudre N, Cougoul P, Bartolucci P, Dorr G, Bura-Riviere A, Kamar N, et al. Improved Fetal Hemoglobin With mTOR Inhibitor-Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease. Am J Transpl. 2017;17:2212\u20134.","journal-title":"Am J Transpl"},{"key":"2892_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221100648","volume":"13","author":"C Zuccato","year":"2022","unstructured":"Zuccato C, Cosenza LC, Zurlo M, Gasparello J, Papi C, D\u2019Aversa E, et al. Expression of gamma-globin genes in beta-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin). Ther Adv Hematol. 2022;13:20406207221100648.","journal-title":"Ther Adv Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02892-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02892-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02892-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:36:39Z","timestamp":1775558199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02892-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02892-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSJ is currently an employee of Merck. MS served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi, and Syndax, Kura; consulted for Boston Consulting, GLG, and Dedham group; and participated in CME activity for Novartis, Curis Oncology, Haymarket Media, and Clinical Care Options, and is a member of the Medical Safety Monitoring Board for Keros Pharmaceuticals. AM has received research funding from Morphic and has consulted for Cellarity.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}